obinutuzumab
NICE approves Roche’s Gazyvaro and Novartis’ Xolair
March 11, 2015Research and Development, Sales and Marketing Gazyvaro, NICE, Novartis, Roche, Xolair, obinutuzumab, omalizumab
NICE today gave the green light to three new biological drugs, after recommending Roche’s Gazyvaro, GSK’s Arzerra and Novartis’ Xolair …
Late-stage successes for Amgen and Roche
February 5, 2015Sales and Marketing Amgen, Bendamustine, Gazyva, Genentech, Humira, Levact, Napp, Roche, adalimumab, obinutuzumab
Roche and Amgen have both posted successful late-stage trial results that they say will contribute to their applications for regulatory …
NICE U-turn on Roche leukaemia drug
December 2, 2014Sales and Marketing Gazyvaro, MabThera, NHS, NICE, Roche, leukaemia, obinutuzumab
NICE has reversed its decision on Roche’s chronic lymphocytic leukaemia (CLL) drug Gazyvaro only two months after rejecting the drug. …
New Roche leukaemia drug beats rival
July 24, 2013Research and Development, Sales and Marketing Rituxan, Roche, leukaemia, obinutuzumab
Roche’s next generation leukaemia drug obinutuzumab has beaten the firm’s ageing blood cancer medicine Rituxan in a late-stage trial. The …
Roche leukaemia drug granted speedy US review
July 3, 2013Research and Development, Sales and Marketing CLL, FDA, Roche, leukaemia, obinutuzumab
Roche’s investigational leukaemia drug could be available for US patients by the end of the year as the FDA looks …
